Back to search results
NCT03623672

North American Prodromal Synucleinopathy Consortium

Enrolling by Invitation
Not specifiedAges 18+Observational
Washington University School of Medicine
~500 participants
Updated 2024-11-06 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prodromal Synucleinopathy Rating Scale
Measured over 2 years

Conditions

REM Sleep Behavior Disorder
Parkinson Disease
Lewy Body Disease
Dementia With Lewy Bodies
Multiple System Atrophy
REM Sleep Parasomnias

Explore related trials

REM sleep behavior disorder

Where it's being run

10 sites across 8 states
California2
Minnesota2
Arizona1
Georgia1
Massachusetts1
Missouri1
Oregon1
Quebec1

Study leadership

  • Yo-El Ju, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
  • Bradley Boeve, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Idiopathic REM sleep behavior disorder

Exclusion

REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia, Parkinson's Disease, etc)
Other neurological disorder

What this trial measures

  • Prodromal Synucleinopathy Rating Scale2 years

    Rating scale combining neurocognitive battery, motor, autonomic, olfaction, color vision functions. Global score range 0-3, with higher score indicating greater symptoms of synucleinopathy.